Managing Human Rights in Health and Life Science Value Chain

Health and life sciences companies are facing growing expectations to operationalize human rights across the value chain, driven by upcoming regulations such as the EU Corporate Sustainability Due Diligence Directive (CSDDD) and evolving customer requirements. In this closed door roundtable discussion, leaders will share candid insights on challenges and emerging practices related to improving supply chain visibility, strengthening third party risk management, and supporting the delivery of affordable and accessible medicines - moving beyond compliance to drive business resilience.

Join EY for an in person, closed door human rights roundtable for pharmaceutical leaders. Together, we will explore:

• How companies are strengthening human rights due diligence across complex, multi tier supply chains in anticipation of CSDDD and customer contractual requirements 
• Practical approaches to improving upstream supply chain visibility, identifying forced labor and human rights risks, and integrating third party risk management into existing processes 
• How leading organizations are balancing compliance, business continuity, and access to affordable and accessible medicines 

Who should attend:

Management teams accountable for execution, including:

• Sustainability/ESG leaders 
• Supply Chain, Manufacturing, Procurement, Supplier Management 

The session will feature a brief EY perspective followed by a roundtable discussion, enabling candid exchange on implementation challenges, lessons learned, and how organizations are preparing for the next phase of human rights regulation. Participants will leave with practical ideas for prioritizing risk, aligning internal stakeholders, and strengthening human rights due diligence in a way that supports resilience and long term value creation.

Additional information:

• This event will be held in English